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Abstract
The membrane transporter AT‐1/SLC33A1 translocates cytosolic acetyl‐CoA into the
lumen of the endoplasmic reticulum (ER), participating in quality control mechanisms
within the secretory pathway. Mutations and duplication events in AT‐1/SLC33A1 are
highly pleiotropic and have been linked to diseases such as spastic paraplegia, devel-
opmental delay, autism spectrum disorder, intellectual disability, propensity to sei-
zures, and dysmorphism. Despite these known associations, the biology of this key
transporter is only beginning to be uncovered. Here, we show that systemic overex-
pression of AT‐1 in the mouse leads to a segmental form of progeria with dysmor-
phism and metabolic alterations. The phenotype includes delayed growth, short
lifespan, alopecia, skin lesions, rectal prolapse, osteoporosis, cardiomegaly, muscle
atrophy, reduced fertility, and anemia. In terms of homeostasis, the AT‐1 overexpress-
ing mouse displays hypocholesterolemia, altered glycemia, and increased indices of
systemic inflammation. Mechanistically, the phenotype is caused by a block in Atg9a‐
Fam134b‐LC3β and Atg9a‐Sec62‐LC3β interactions, and defective reticulophagy, the
autophagic recycling of the ER. Inhibition of ATase1/ATase2 acetyltransferase
enzymes downstream of AT‐1 restores reticulophagy and rescues the phenotype of
the animals. These data suggest that inappropriately elevated acetyl‐CoA flux into the
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ER directly induces defects in autophagy and recycling of subcellular structures and
that this diversion of acetyl‐CoA from cytosol to ER is causal in the progeria pheno-
type. Collectively, these data establish the cytosol‐to‐ER flux of acetyl‐CoA as a novel
event that dictates the pace of aging phenotypes and identify intracellular acetyl‐CoA‐
dependent homeostatic mechanisms linked to metabolism and inflammation.
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1 | INTRODUCTION
Nε‐lysine acetylation in the lumen of the endoplasmic reticulum (ER)
has emerged as a novel mechanism for the regulation of protein home-
ostasis (also referred to as proteostasis) within the organelle (Ding,
Dellisanti, Ko, Czajkowski, & Puglielli, 2014; Hullinger et al., 2016;
Jonas, Pehar, & Puglielli, 2010; Pehar, Jonas, Hare, & Puglielli, 2012;
Peng & Puglielli, 2016; Peng et al., 2014, 2016). Acetylation of ER
cargo proteins is ensured by three essential elements: AT‐1, ATase1,
and ATase2. AT‐1 (also referred to as SLC33A1) is the ER membrane
transporter that regulates the cytosol‐to‐ER flux of acetyl‐CoA, donor
of the acetyl group in the reaction of Nε‐lysine acetylation (Jonas
et al., 2010; Peng et al., 2014). ATase1 (also referred to as NAT8B) and
ATase2 (also referred to as NAT8) are type II ER membrane proteins
that carry out the reaction of Nε‐lysine acetylation within the ER
lumen (Ding et al., 2014; Ko & Puglielli, 2009). Ex vivo and in vivo data
suggest that the ER acetylation machinery is a component of ER qual-
ity control and regulates two essential functions of the organelle: (a)
selection and transport of cargo proteins along the secretory pathway;
and (b) disposal of protein aggregates that form within the ER and
secretory pathway (Ding et al., 2014; Hullinger et al., 2016; Pehar
et al., 2012; Peng & Puglielli, 2016; Peng et al., 2014, 2016). The for-
mer requires the ATases to associate with the oligosaccharyltrans-
ferase complex (OST) and acetylate correctly folded polypeptides
(Ding et al., 2014; Peng & Puglielli, 2016) while the latter requires
acetylation/deacetylation of the autophagy protein Atg9a (Pehar et al.,
2012; Peng & Puglielli, 2016; Peng et al., 2014, 2016 ). AT‐1 regulates
availability of acetyl‐CoA within the ER; as such, it plays crucial regula-
tory functions for the entire ER acetylation machinery.
Clinically, diverse outcomes related to genetic deficiency, muta-
tion, or overabundance of AT‐1 have been identified. Children with
homozygous mutations in AT‐1/SLC33A1 display congenital defects,
severe developmental delay, and premature death (Chiplunkar et al.,
2016; Huppke et al., 2012). Patients with heterozygous mutations
appear normal at birth but then develop a complicated autosomal
dominant form of spastic paraplegia (Lin et al., 2008). Finally, chromo-
somal duplications of the 3q25.31 locus, which harbors AT‐1/
SLC33A1, have been reported in patients with autism spectrum disor-
der (ASD), intellectual disability, propensity to seizures, and facial dys-
morphism (SFARI database; see also Swisshelm et al. 2014. ASHG
Annual Meeting; Abstract 3205 T). The above disease phenotypes are
mimicked by related mouse models. Knock‐in mice that lack AT‐1
activity (AT‐1S113R/S113R) die during embryogenesis, while mice with
haploinsufficiency of AT‐1 (AT‐1S113R/+) develop neurodegeneration
with spasticity and propensity to infections and cancer (Peng et al.,
2014). Transgenic mice that overexpress AT‐1 in forebrain neurons
(AT‐1 Tg) display an ASD‐like phenotype without dysmorphism (Hul-
linger et al., 2016). Mechanistically, the phenotype of AT‐1S113R/+ mice
is linked to aberrant activation of autophagy (Peng et al., 2014) while
the phenotype of AT‐1 Tg is linked to increased efficiency of the
secretory pathway (Hullinger et al., 2016). When taken together, the
convergence of human‐ and mouse‐based studies clearly indicates that
the ER acetylation machinery plays fundamental biological functions.
Despite these known associations, the biology of AT‐1 and the
ER acetylation machinery is only beginning to be uncovered. Here,
we sought to investigate the broader consequences of AT‐1 manipu-
lation, including the cellular and systemic impact of AT‐1‐directed
changes in ER acetylation, by generating a transgenic mouse where
AT‐1 was placed under the control of the Rosa26 locus. The animals
developed a severe phenotype mimicking segmental forms of human
progerias. At a mechanistic level, we observed increased acetylation
of the ER‐localized autophagy protein Atg9a, reduced Atg9a‐
Fam134b‐LC3β and Atg9a‐Sec62‐LC3β interaction, and a block in
ER‐autophagy/reticulophagy. Finally, we showed that a specific
ATase1/ATase2 inhibitor, which restores ER proteostatic functions
downstream of AT‐1, was able to rescue the entire phenotype of
the animals, including the lifespan. Collectively, these data establish
the cytosol‐to‐ER flux of acetyl‐CoA as a novel event that dictates
the pace of aging phenotypes and identify intracellular acetyl‐CoA‐
dependent homeostatic mechanisms linked to metabolism and
inflammation.
2 | RESULTS
2.1 | AT‐1 sTg mice display a progeria‐like
phenotype
To study the systemic role of AT‐1, we generated transgenic (Tg)
mice with an inducible overexpression Tet‐Off system driven by the
Rosa26 locus (Figure 1a,b). For the purpose of this study, the ani-
mals (referred to as AT‐1 sTg) were maintained in the absence of
doxycycline (Dox); therefore, they overexpressed AT‐1 throughout
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their entire life, including development. The animals were born with
Mendelian ratio and were completely normal at birth. However,
within 1 month they appeared smaller than their wild‐type/non‐Tg
(WT) littermates (Figure 1c), and within 2 months they displayed a
severe phenotype (Figure 1c and Table 1) that was reminiscent of
segmental forms of human progerias (Gonzalo, Kreienkamp, & Ask-
jaer, 2017; Karikkineth, Scheibye‐Knudsen, Fivenson, Croteau, &
Bohr, 2017; Liao & Kennedy, 2014; Pivnick et al., 2000). Indeed,
they remained smaller throughout their entire lifespan (Figure 1d),
appeared phenotypically old (Figure 1c), and displayed a very short
lifespan (Figure 1e). The progeria‐like features of the animals are
listed in Table 1.
In addition to being small, AT‐1 sTg mice were very thin and had
small fat pads (Figure 2a,b); the significant reduction in fat tissue
was observed despite the fact that they ate more than their WT lit-
termates (Figure 2c). AT‐1 sTg mice also displayed small areas of
muscle atrophy (Figure 2d). However, relative to their body weight,
they had overall enlarged organs (Figure 2e); the only exception was
the uterus, which appeared significantly smaller and atrophic (Fig-
ure 2e; see Inset). This finding is in line with the observed reduced
fertility of female animals (Table 1). The skin displayed hair loss, mul-
tiple lesions, and delayed wound repair (Figures 1c and 2f; Table 1).
Histologically, we observed dermatitis with marked acanthosis and
moderate orthokeratotic hyperkeratosis, reactive fibrosis, and epider-
mal hyperplasia (Figure 2g). Most of the animals also developed
rectal prolapse (Figure 2f). Both male and female AT‐1 sTg mice dis-
played severe bone density loss, which was reminiscent of human
osteoporosis (Figure 2h–j). In line with the postmortem data (Fig-
ure 2e), echocardiographic assessment of living animals confirmed
that AT‐1 sTg mice suffered from cardiomegaly very early in life (Fig-
ure 2k,l).
2.2 | AT‐1 sTg mice display defective
hematopoiesis, metabolic alterations, and systemic
inflammation
A complete blood count of AT‐1 sTg mice revealed mild‐to‐moder-
ate anemia, which was well evident in females (Figure 3a). The
anemia was accompanied by splenomegaly and expansion of the
spleen interfollicular/red pulp (extramedullary hematopoiesis) in
both males and females (Figure 3b). We also observed reduced
levels of circulating ferritin (Supporting Information Figure S1a)
and iron (Supporting Information Figure S1b), increased reticulo-
cyte ratio in the peripheral blood (Figure 3c), and reduced erythro-
cyte/nucleated ratio in the bone marrow (Figure 3d). Further
assessment revealed a marked increase in erythroid progenitor
activity in AT‐1 sTg spleens relative to WT (Figure 3e,f). When
taken together, the above results indicate that AT‐1 overexpres-
sion disrupts steady‐state hematopoiesis, causing splenomegaly and
extramedullary erythropoiesis.
F IGURE 1 AT‐1 sTg mice are smaller and have a short lifespan. (a) AT‐1 sTg mice were generated with an inducible Tet‐Off expression
system under the control of the Rosa26 locus for systemic overexpression. (b) Western blots showing AT‐1 overexpression in different tissues
(1, WT; 2, AT‐1 sTg). (c) Representative AT‐1 sTg mouse and WT littermate when 28 and 55 days old. (d) Body weight of male and female WT
and AT‐1 sTg mice across their lifespan. (e) Lifespan of AT‐1 sTg mice (maximum lifespan, males = 142 days, females = 147 days, p < 0.0005;
median lifespan, males = 96 days, females = 81 days, p < 0.0005). Bars represent mean ± SD. *p < 0.05; **p < 0.005; #p < 0.0005
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Metabolic assessment of AT‐1 sTg mice revealed reduced levels
of circulating glucose and insulin (Figure 3g,h) but normal levels of
glucagon (Supporting Information Figure S2a). Lower levels of plasma
glucose and insulin were also observed following an oral glucose tol-
erance test (Figure 3i,j and Supporting Information Figure S2b,c) sug-
gesting a more effective utilization of glucose. The metabolic
assessment of the animals also revealed reduced levels of circulating
cholesterol (Figure 3k).
Postmortem examination of AT‐1 sTg mice revealed enlarged
lymph nodes (Figure 4a) as well as histological evidence for moder-
ate inflammatory infiltration across different tissues and organs,
indicative of systemic inflammation. Consistently, we observed
increased levels of several inflammatory molecules in the plasma
(Figure 4b) as well as a marked immunoglobulin infiltration of periph-
eral tissues (Figure 4c–f). The increased systemic inflammation in AT‐
1 sTg mice was also reflected in the significant increase in B cells
and neutrophils in the peripheral blood relative to WT (Figure 4g,h).
Chronic tissue inflammation is often associated with markers of cel-
lular senescence (Jeon et al., 2017; Kang et al., 2015; Ovadya & Kriz-
hanovsky, 2014; Tchkonia, Zhu, Deursen, Campisi, & Kirkland, 2013).
Therefore, we used isolated hepatocytes and liver sections to
determine levels of p16, p21, and senescence‐associated β‐galactosi-
dase (SA‐β‐Gal), three established markers of cell senescence (Jeon
et al., 2017; Kang et al., 2015; Ovadya & Krizhanovsky, 2014;
Tchkonia et al., 2013). We consistently found increased levels of the
senescent markers in AT‐1 sTg mice when compared to WT litter-
mates (Figure 4i–l). These results were paralleled by a significant
reduction in the proliferation potential of mouse embryonic fibrob-
lasts (MEF) in culture (Figure 4m,n).
2.3 | AT‐1 sTg mice display defective reticulophagy
The above results indicate that systemic overexpression of AT‐1
causes a complex phenotype that resembles human segmental
progerias with metabolic alterations. We previously reported that
the influx of acetyl‐CoA from the cytosol to the ER lumen by AT‐1
regulates the induction of ER‐autophagy and the disposal of protein
aggregates within the secretory pathway (Jonas et al., 2010; Pehar
et al., 2012; Peng & Puglielli, 2016; Peng et al., 2014, 2016 ). There-
fore, it is possible that a defect in ER‐autophagy (also referred to as
reticulophagy) is at the basis of the progeria‐like phenotype of AT‐1
sTg mice.
To test the above hypothesis, we first analyzed the acetylation
profile of the autophagy protein Atg9a, which is essential for the
induction of autophagy downstream of the ER acetylation machinery
(Pehar et al., 2012; Peng & Puglielli, 2016; Peng et al., 2014, 2016 ). In
fact, Atg9a undergoes acetylation on two lysine residues, K359 and
K363, which face the lumen of the ER (Pehar et al., 2012). Acetylated
Atg9a blocks the induction of autophagy while nonacetylated Atg9a
exerts the opposite effect (Pehar et al., 2012). Direct assessment of ER
membranes from WT and AT‐1 sTg mice revealed a marked increase
in the acetylation status of Atg9a in the transgenic animals (Figure 5a,
b), thus supporting our hypothesis. To assess whether the increased
acetylation of Atg9a was accompanied by reduced disposal of mis-
folded/aggregated ER cargo proteins, we took advantage of the pro‐
aggregating properties of the A53 T mutant form of α‐synuclein (A53
T syn; Polymeropoulos et al., 1997). Specifically, we used A53 T syn
with a signal peptide (SP) at the N‐terminus to direct translation on the
ER and insertion into the secretory pathway (Peng et al., 2016). The
results show that when expressed in MEF, the levels of aggregated/
SDS soluble SP‐A53 T syn were higher in AT‐1 sTg vs. WT animals
(Supporting Information Figure S3a,b). This finding is consistent with
previous data, where we showed a more efficient clearance of SP‐A53
T syn in MEF from AT‐1S113R/+ mice, which display reduced AT‐1
activity, reduced acetylation of Atg9a, and increased induction of ER‐
autophagy (Peng et al., 2016). Therefore, when taken together, data
from two different animal models, AT‐1 sTg (present study) and AT‐
1S113R/+ (Peng et al., 2016) mice, as well as cellular systems (Pehar
et al., 2012), support the conclusion that the increased acetylation of
Atg9a in AT‐1 sTg mice is causally linked to reduced ability of the ER
to dispose of toxic protein aggregates that form within its lumen (see
also later).
Previous data in MEF from AT‐1S113R/+ mice and H4 cells over-
expressing AT‐1 indicate that changes in autophagy induction
TABLE 1 Observed phenotype of AT‐1 sTg mice
Median lifespan Greatly reduced (males, 96 days; females,
81 days)




Major organ mass Increased (exception: uterus, decreased)
Fertility Males, normal; females, reduced
Adipose tissue Reduced




Hair regrowth Greatly reduced
Skin lesions Pronounced
Wound repair Retarded
Muscle atrophy Modest to severe






Peripheral WBC Altered (B cell and neutrophil expansion)
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downstream of AT‐1 are also paralleled by changes in efficiency of
the secretory pathway; specifically, reduced AT‐1 activity leads to
reduced trafficking of newly synthesized glycoproteins along the
secretory pathway while increased AT‐1 activity leads to the oppo-
site effect (Hullinger et al., 2016). To test whether this was indeed
the case in AT‐1 sTg mice, we used azide‐modified mannosamine
(ManNAz) to label sialic acid‐containing newly synthesized glycopro-
teins that have successfully trafficked from the ER to the trans‐Golgi
(Hullinger et al., 2016). The results show a significant increase in the
levels of ManNAz incorporation in hepatocytes from AT‐1 sTg ani-
mals (Supporting Information Figure S3c). Therefore, when taken
together, the combined use of SP‐A53 T syn and ManNAz confirm
F IGURE 2 AT‐1 sTg mice display progeria‐like features. (a) Examination of WT and AT‐1 sTg mice. Reduced fat accumulation and
splenomegaly are evident in both AT‐1 sTg males and females. (b) Total body fat in WT and AT‐1 sTg mice as determined by dual‐energy X‐
ray (DEXA) scanning (males, n = 7; females, n = 8). (c) Food intake of WT and AT‐1 sTg mice (males, n = 5; females, n = 5). (d) Skeletal muscle
histology. (e) Weight of major organs. Inset shows uterus. (f) Skin alterations and rectal prolapse in AT‐1 sTg mice. (g) H&E staining of a skin
section from AT‐1 sTg mice. (h, i) Faxitron X‐ray (femur) (h) and bone mineral density (i) of WT and AT‐1 sTg mice (WT, n = 8; AT‐1 sTg,
n = 8). (j) Goldner's trichrome stain of femur sections. (k, l) Echocardiographic assessment of WT and AT‐1 sTg mice (WT, n = 8; AT‐1 sTg,
n = 8). Bars represent mean ± SD. *p < 0.05, **p < 0.005, #p < 0.0005. LVID: d, left ventricular internal diameter end diastole; LVPW: d, left
ventricular posterior wall end diastole; LVAW: d, left ventricular anterior wall end diastole
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F IGURE 3 AT‐1 sTg mice display defective hematopoiesis, and reduced levels of circulating glucose, insulin, and cholesterol. (a)
Hematologic parameters of WT and AT‐1 sTg mice (males, n = 4; females, n = 6). (b) Representative images of whole spleen from WT and AT‐
1 sTg mice. (c, d) Quantitative blood (c) and bone marrow (d) smears in WT and AT‐1 sTg mice (males, n = 4; females, n = 4). (e) Quantitation
(left) and representative images (right) of colony‐forming unit‐erythroid (CFU‐E) colonies 2 days after plating splenic cells (1 × 105) from WT
(n = 3) and AT‐1 sTg (n = 3) mice in methylcellulose containing Epo, SCF, IL‐3, and IL‐6. (f) Quantitation (left) and representative images (right)
of burst‐forming unit‐erythroid (BFU‐E) colonies 5 days after plating splenic cells (1 × 105) from WT (n = 3) and AT‐1 sTg (n = 3) mice in
methylcellulose containing Epo, SCF, IL‐3, and IL‐6. (g, h) Fasting levels of glucose (g) and insulin (h) in plasma (males, n = 5; females, n = 5). (i,
j) Oral glucose tolerance test (OGTT) in WT and AT‐1 sTg mice (males, n = 5; females, n = 5). AUCglucose (i) and AUCinsulin (j) are shown. (k)
Plasma lipid profile in WT and AT‐1 sTg mice (males, n = 5; females, n = 5). Bars represent mean ± SD. *p < 0.05, **p < 0.005, #p < 0.0005.
WBC: white blood cells; RBC: red blood cells; HCT: hematocrit; Hb: hemoglobin. WBC: white blood cells; RBC: red blood cells; HCT:
hematocrit; Hb: hemoglobin
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F IGURE 4 AT‐1 sTg mice display systemic and tissue inflammation. (a) Weight of axillary lymph nodes in WT and AT‐1 sTg mice (n = 6 per
group). (b) Plasma inflammatory markers (out of a total of 42 different analytes tested). In red, analytes that were changed in both males and
females (males, n = 6; females, n = 6). (c, d) Dot blot of tissue immunoglobulins determined with anti‐mouse IgG. Representative images (c) and
quantitation of results (d) are shown. The analysis was carried out in liver (WT, n = 3; AT‐1 sTg, n = 3). (e, f) Western blot showing tissue
immunoglobulins determined with anti‐mouse IgG. Representative images (e) and quantitation of results (f) are shown. The analysis was carried
out in liver (WT, n = 3; AT‐1 sTg, n = 3). (g, h) Flow cytometry showing B cell (g), and neutrophil (h) population in bone marrow and peripheral
blood (WT, n = 3; AT‐1 sTg, n = 3). (i) Western blot showing p16 levels in liver. Representative images (left panel) and quantitation of results
(right panel) are shown (WT, n = 7; AT‐1 sTg, n = 7). (j) p21 mRNA quantitation in liver (WT, n = 7; AT‐1 sTg, n = 7). (k, l) SA‐β‐Gal staining in
liver and hepatocytes. Representative images (k) and quantitation of results (l) are shown (WT, n = 3; AT‐1 sTg, n = 3). (m, n) Proliferation
potential of cultured MEF expressed as proliferation rate at each passage (m; n = 3 different MEF lines/group) and as cell number after plating
(n; n = 3 different MEF lines/group). Bars represent mean ± SD. *p < 0.05, **p < 0.005, #p < 0.0005. EC: extracellular; FA: formic acid‐soluble;
Hc: heavy chain; IC: intracellular; Lc: light chain; MB: membrane‐bound
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F IGURE 5 AT‐1 sTg mice display defective reticulophagy and expansion of the ER. (a, b) Western blot showing levels of acetylated‐Atg9a
(Atg9a‐Ac) in ER preparations from liver. Representative blots are shown in (a) while quantitation of results is shown in (b) (WT, n = 3; AT‐1
sTg, n = 3). (c) Structure illumination microscopy (SIM) of ER in isolated hepatocytes showing size and morphology of sheet‐like structures. (d,
e) SIM showing Fam134b puncta on ER of isolated hepatocytes. Quantitation of results is shown in (e) (WT, n = 8; AT‐1 sTg, n = 7). (f)
Fam134b mRNA quantitation in liver (WT, n = 6; AT‐1 sTg, n = 5). (g, h) Western blot showing levels of Fam134b in ER preparations.
Representative blots are shown in (g) while quantitation of results is shown in (h) (WT, n = 4; AT‐1 sTg, n = 4). (i, j) SIM showing reduced
Fam134b/LC3β co‐localization on ER of isolated hepatocytes from AT‐1 sTg mice. Quantitation of results is shown in (j) (WT, n = 5; AT‐1 sTg,
n = 5). (k, l) Western blot showing co‐immunoprecipitation of Atg9a and Fam134b in WT and AT‐1 sTg mice. Representative blots are shown
in (k) while quantitation of results is shown in (l) (WT, n = 8; AT‐1 sTg, n = 8). (m, n) SIM showing reduced Sec62/LC3β co‐localization on ER of
isolated hepatocytes from AT‐1 sTg mice. Quantitation of results is shown in (n) (WT, n = 5; AT‐1 sTg, n = 5). (o, p) Western blot showing co‐
immunoprecipitation of Atg9a and Sec62 in WT and AT‐1 sTg mice. Representative blots are shown in (o) while quantitation of results is
shown in (p) (WT, n = 7; AT‐1 sTg, n = 7). Bars represent mean ± SD. *p < 0.05, **p < 0.005, #p < 0.0005. N: nucleus
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the conclusion that changes in reticulophagy in AT‐1 sTg mice are
closely paralleled by opposite changes in the transport of cargo pro-
teins along the secretory pathway. These results are in line with pre-
vious data (Hullinger et al., 2016; Peng & Puglielli, 2016).
In addition to reduced elimination of toxic protein aggregates, a
significant block in reticulophagy is expected to cause structural
reorganization of the organelle. To determine whether this was
indeed the case, we used super‐resolution microscopy, specifically
structured illumination microscopy (SIM). Consistent with our predic-
tion, we observed a profound reorganization of the ER in AT‐1 sTg;
particularly, we observed expansion of the organelle and enlarged
sheet‐like structures (Figure 5c and Supporting Information Fig-
ure S3d). Even when comparing similar structures in WT and AT‐1
sTg mice, the transgenic animals displayed a marked membrane pro-
liferation with numerous processes emerging from the ER sheets
(Figure 5c; discussed later).
2.4 | AT‐1 sTg mice display reduced Atg9a‐
Fam134b‐LC3β and Atg9a‐Sec62‐LC3β interaction
The role of Atg9a as a potential “sensor” of the acetylation status of
the ER has already been described (Pehar et al., 2012; Peng & Pug-
lielli, 2016; Peng et al., 2014, 2016). Thus, the above results are not
surprising. However, what remains to be determined is how the
acetylation of Atg9a on K359 and K363 within the lumen of the ER
can activate the core of the autophagy machinery, which is mainly
cytosolic (Klionsky et al., 2016). Interestingly, the above two lysine
residues are flanked by two coiled regions that could be involved
with protein–protein interactions (Pehar et al., 2012). This might sug-
gest that the acetylation status of Atg9a regulates the interaction
with other ER‐luminal or membrane‐bound partners. However, as
the core of the autophagy machinery is mainly cytosolic, a mem-
brane‐bound protein is more likely to connect an ER‐luminal event,
acetylation of Atg9a, to the autophagy core machinery, specifically
LC3β.
To address the above scenario and dissect the mechanism
responsible for the block in reticulophagy, we studied levels and ER
association of Fam134b, a recently identified key regulator of reticu-
lophagy (Khaminets et al., 2015; Mochida et al., 2015; Rubinsztein,
2015). Interestingly, the ER expansion in AT‐1 sTg mice was accom-
panied by a marked increase in the number of Fam134b puncta on
the ER membrane (Figure 5d,e). The upregulation of Fam134b in AT‐
1 sTg mice was also observed when we analyzed mRNA (Figure 5f)
and protein levels (Figure 5g,h). Fam134b has recently emerged as a
novel regulator of ER‐autophagy, and levels of Fam134b seem to
reflect intrinsic dynamics of reticulophagy (Khaminets et al., 2015;
Lennemann & Coyne, 2017; Mochida et al., 2015; Nakatogawa &
Mochida, 2015; Rubinsztein, 2015). Therefore, increased steady‐state
levels of Fam134b in AT‐1 sTg mice (Figure 5d–h) are consistent
with the observed ER expansion (Figure 5c and Supporting Informa-
tion Figure S3d), as they might reflect reduced turnover of the ER‐
associated Fam134b protein as well as an attempt of the cell to
restore reticulophagy by activating Fam134b translation. Fam134b
has a LC3‐interacting region (LIR) on its C‐terminus, which is
required for binding to cytosolic LC3β (also referred to as Atg8 in
yeast; Khaminets et al., 2015; Mochida et al., 2015; Rubinsztein,
2015). Fam134b‐LC3β interaction is required for efficient induction
of reticulophagy (Khaminets et al., 2015; Mochida et al., 2015;
Rubinsztein, 2015). Notably, despite the increased levels of
Fam134b, we observed a marked reduction in Fam134b‐LC3β co‐lo-
calization in AT‐1 sTg vs. WT (Figure 5i,j).
The finding that AT‐1 sTg mice display less Fam134b‐LC3β inter-
action led us to hypothesize that Atg9a, which acts as a sensor of
ER acetylation (Pehar et al., 2012), might engage with Fam134b
within the ER membrane. Indeed, immunoprecipitation of Atg9a
from the ER membrane was able to pull‐down Fam134b (Figure 5k,
l); however, this interaction was markedly reduced in AT‐1 sTg mice
(Figure 5k,l) suggesting that the increased acetylation of Atg9a (Fig-
ure 5a) impedes functional interaction (see also later). The reduced
Atg9a‐Fam134b association in AT‐1 sTg mice was observed despite
the fact that we consistently pulled down more Atg9a from the ER
of the Tg animals compared to WT littermates (Figure 5k) and that
Fam134b is upregulated in the Tg animals (Figure 5g; see also later).
Another important regulator of reticulophagy is Sec62, a member
of the ER membrane translocon complex, which regulates import of
newly synthesized proteins within the ER (Fumagalli et al., 2016).
Like Fam134b, Sec62 also has a LIR domain, which is required for
binding to LC3β; increased Sec62‐LC3β interaction promotes reticu-
lophagy and delivery of ER cargo proteins to autolysosomes (Fuma-
galli et al., 2016). As with Fam134b, SIM imaging revealed a marked
reduction in Sec62‐LC3β co‐localization in AT‐1 sTg vs. WT animals
(Figure 5m,n). Furthermore, direct biochemical assessment revealed
that Atg9a is able to engage Sec62 at the ER membrane; however,
the Atg9a‐Sec62 interaction was greatly reduced in the AT‐1 sTg
mice (Figure 5o,p). Again, this was observed even though we pulled
down more Atg9a from the ER of the Tg animals (Figure 5o). SIM
imaging showed that Fam134b‐LC3β and Sec62‐LC3β co‐localization
can be observed on the ER membrane (Supporting Information Fig-
ure S3e), suggesting that the initial interaction of Fam134b and
Sec62 with LC3β can occur on the ER itself prior to the formation of
the autophagosome. This process is blocked in AT‐1 sTg mice (Fig-
ure 5i–p).
When taken together, the above results suggest that AT‐1 over-
expression and increased cytosol‐to‐ER flux of acetyl‐CoA leads to
increased acetylation of Atg9a and reduced Atg9a‐Fam134b and
Atg9a‐Sec62 interaction within the ER membrane; this prevents
interaction with LC3β, thus causing a block in the induction of retic-
ulophagy. Defective reticulophagy is then accompanied by expansion
of the organelle. In essence, the acetylation status of Atg9a appears
to regulate Fam134b‐LC3β and Sec62‐LC3β interaction and conse-
quent induction of reticulophagy (also discussed later).
The insulin growth factor 1 (Igf‐1) and its receptor (Igf‐1r; Ken-
yon, 2005; Longo & Finch, 2003; Milman, Huffman, & Barzilai,
2016), as well as the stemness potential of stem cells (Garcia‐Prat
et al., 2016; Garcia‐Prat, Sousa‐Victor, & Munoz‐Canoves, 2017),
represent already established age‐associated pathways. To determine
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whether they were mechanistically involved—at least in part—in the
AT‐1 sTg phenotype, we analyzed whole tissue activation of Igf‐1r
signaling (Supporting Information Figure S4a,b); we also treated cul-
tured MEF with Igf‐1 (Supporting Information Figure S4c,d). How-
ever, we did not observe increased Igf‐1r signaling in AT‐1 sTg mice
when compared to WT littermates (Supporting Information Fig-
ure S4). Similarly, no differences were detected in the percentages
of bone marrow Lin−Sca+c‐Kit+ (L−S+K+), multipotent progenitor
(MPP; L−S+K+,CD48+, CD150−), long‐term hematopoietic stem cell
(HSC; LT‐HSC; L−S+K+,CD48−, CD150+), or short‐term HSC (ST‐
HSC; L−S+K+,CD48−, CD150−) populations from bone marrow of
WT and AT‐1 sTg mice, suggesting no intrinsic block in stemness
potential (Supporting Information Figure S5a). Next, we transplanted
WT and AT‐1 sTg bone marrow (CD45.2) into lethally irradiated
recipient mice with CD45.1 spleen cells as a supporting cell popula-
tion and CD45.1 bone marrow cells. Again, no significant differences
in contribution of CD45.2 donor cells to bone marrow were
observed in WT vs. AT‐1 sTg transplantation (Supporting Information
Figure S5b,c).
Many human progeroid syndromes are characterized by nuclear
instability where the primary defect is in the architecture and shape
of the nuclear envelope; associated animal models reproduce the
nuclear instability and mimic the progeroid phenotype (reviewed in
Kubben & Misteli, 2017). However, direct assessment of AT‐1 sTg
mice did not reveal any morphological aberration of the nucleus
(Supporting Information Figure S6).
When taken together, the above results suggest that the reduced
Atg9a‐Fam134b‐LC3β and Atg9a‐Sec62‐LC3β interaction, and the
consequent block in reticulophagy with changes in efficiency of the
secretory pathway are solely responsible for the progeria‐like pheno-
type of AT‐1 sTg mice.
2.5 | Inhibition of the ATases rescues the AT‐1 sTg
phenotype
In addition to AT‐1, which maintains the supply of acetyl‐CoA to the
ER lumen, the acetylation machinery includes two acetyltransferases,
ATase1 and ATase2, which use acetyl‐CoA to carry out the reaction
of Nε‐lysine acetylation (Ko & Puglielli, 2009). The ATases are ER‐
resident membrane proteins and act downstream of AT‐1 (see Fig-
ure 6a). We previously reported the identification of ATase1/
ATase2‐specific inhibitors (Ding et al., 2012); we also reported the
successful use of one of these compounds (6‐chloro‐5H‐benzo[a]
phenoxazin‐5‐one; referred to as compound 9) in a mouse model of
Alzheimer's disease (Peng et al., 2016). Compound 9 is a powerful
inhibitor of both ATases (Ding et al., 2012); it reduces the acetyla-
tion of Atg9a, improves the proteostatic functions of the ER, and is
orally absorbed (Peng et al., 2016). Therefore, we treated AT‐1 sTg
mice with oral formulations of the compound (50 mg kg−1 day−1;
Peng et al., 2016). We argued that if indeed the AT‐1 sTg phenotype
is caused by defective reticulophagy and defective elimination of
toxic protein aggregates that form within the ER, then restoring the
proteostatic functions of the ER by acting downstream of AT‐1 is
expected to ameliorate or rescue the phenotype. As an additional
control to this study, we added a group of animals fed a Dox‐con-
taining diet to turn off the expression of AT‐1 itself (see Figure 1a).
In both cases, compound 9 and Dox were administered at weaning
(postnatal day 22–25) when the initial disease phenotypes were
already manifested.
Inhibition of the ATase1 and ATase2 by compound 9 rescued
the progeria‐like phenotype of AT‐1 sTg mice. Indeed, the animals
looked healthy, did not develop skin lesions, alopecia, rectal prolapse,
or lordokyphosis (Figure 6b,c), and were able to gain weight as a
function of age (Figure 6d). Importantly, compound 9 also rescued
the lifespan of the animals (Figure 6e). Postmortem analysis of 8‐
month‐old animals confirmed our general assessment. Compound 9‐
treated mice had normal fat pads and did not display muscle atrophy
(Figure 6f). A complete blood count showed no evidence of anemia,
which was paralleled by a normal sized spleen and no evidence of
extramedullary erythropoiesis (Supporting Information Figure S7a,b).
The lymph nodes were overall normal (Supporting Information Fig-
ure S7c); this result was paralleled by normalization of circulating
inflammatory molecules (Supporting Information Figure S7d) and the
absence of SA‐β‐Gal activation (Supporting Information Figure S7e,f).
Compound 9‐treated mice also displayed normal bone mineral den-
sity (Supporting Information Figure S7g). Finally, compound 9 was
able to rescue the metabolic aspects of the AT‐1 sTg phenotype,
including food intake (Supporting Information Figure S7h), circulating
levels of glucose (Supporting Information Figure S7i), and choles-
terolemia (Supporting Information Figure S7j).
Next, we determined Atg9a‐Fam134b interaction as well as
levels of Fam134b on ER structures following compound 9 treat-
ment. Again, we observed that AT‐1 sTg mice displayed reduced
Atg9a‐Fam134 interaction and increased ER membrane‐associated
Fam134b levels; however, both findings were completely normalized
by compound 9 treatment (Figure 7a–d). Indeed, compound 9
restored Atg9a‐Fam134b interaction (Figure 7a,b) and normalized
Fam134b levels (Figure 7c,d). A similar result was observed with
Sec62. In fact, compound 9 restored the Atg9a‐Sec62 interaction at
the ER membrane (Figure 7e,f). Finally, compound 9 rescued the
membrane expansion and reorganization of the ER observed in AT‐1
sTg mice (Figure 7g,h).
In conclusion, the above results show that restoring the proteo-
static functions of the ER by inhibiting ATase1 and ATase2 down-
stream of AT‐1 rescues the progeria‐like phenotype of AT‐1 sTg
mice; they also support the notion that a block in Atg9a‐Fam134b‐
LC3b and Atg9a‐Sec62‐LC3β interaction and the consequent defect
in reticulophagy are at the basis of the AT‐1 sTg phenotype (Sup-
porting Information Figure S8). Although with some minor differ-
ences, the rescue elicited by compound 9 treatment was overall
comparable to that of Dox, which in this study acted as our genetic
control (see Figures 6 and 7; Supporting Information Figure S7). It is
also important to stress that for our postmortem analysis, we used
8‐month‐old animals, which corresponds to approximately twice the
lifespan of untreated AT‐1 sTg mice, thus indicating that the protec-
tive effects of compound 9 were long lasting.
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3 | DISCUSSION
3.1 | Increased acetyl‐CoA flux into the ER causes a
progeria‐like phenotype
Acetyl‐CoA is a central metabolite that is key to many biochemical
and cellular pathways. Acetyl‐CoA also acts as the donor of the
acetyl group in all reactions of Nε‐lysine acetylation. Here, we report
that increased acetyl‐CoA flux from the cytosol to the ER lumen, as
caused by systemic overexpression of human AT‐1 in the mouse,
causes a progeria‐like phenotype with metabolic alterations.
Segmental progerias typically manifest with severe debilitating symp-
toms and reduced lifespan. At birth, patients are typically smaller
and display facial dysmorphism; as they grow, they develop a com-
plex phenotype that often mimics accelerated forms of pathogenic
aging. Segmental progerias include Hutchinson–Gilford, Cokayne,
Werner, Bloom, and Rothmund–Thompsons syndromes, among
others (Gonzalo et al., 2017; Karikkineth et al., 2017; Kubben & Mis-
teli, 2017; Swahari & Nakamura, 2016).
Almost all human progeroid syndromes are characterized by
nuclear and/or genomic instability where the primary defect is in the
F IGURE 6 ATase1/ATase2 inhibition rescues the progeria‐like phenotype and lifespan of AT‐1 sTg mice. (a) Schematic view of the ER
acetylation machinery with compound 9 acting on the ATases downstream of AT‐1. (b, c) Representative images of AT‐1 sTg mice with and
without compound 9 treatment. Dox treatment is shown for comparison. Mice at two different ages are shown. (d) Body weight of male and
female AT‐1 sTg mice with and without compound 9 treatment. Dox‐treated AT‐1 sTg mice are shown for comparison (n = 16 for all groups).
(e) Lifespan of AT‐1 sTg mice with and without compound 9 treatment. Dox‐treated AT‐1 sTg mice are shown for comparison (p < 0.0005, all
vs. AT‐1 sTg with chow). (f) Postmortem examination of WT and AT‐1 sTg mice treated with compound 9. Dox treatment is shown for
comparison. Mice were 8 months old when examined. Bars represent mean ± SD. **p < 0.005; #p < 0.0005
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F IGURE 7 ATase1/ATase2 inhibition restores reticulophagy in AT‐1 sTg mice. (a, b) Western blot showing Atg9a‐Fam134b interaction on
the ER membrane of compound 9‐treated AT‐1 sTg mice. Dox‐treated and 3‐month‐old AT‐1 sTg mice are shown for comparison.
Representative blots are shown in (a) while quantitation of results is shown in (b) (n = 6 for all groups). (c, d) Western blot showing ER levels
of Fam134b in compound 9‐treated AT‐1 sTg mice. Dox‐treated and 3‐month‐old AT‐1 sTg mice are shown for comparison. Representative
blots are shown in (c) while quantitation of results is shown in (d) (n = 6 for all groups). (e, f) Western blot showing Atg9a‐Sec62 interaction on
the ER membrane of compound 9‐treated AT‐1 sTg mice. Dox‐treated and 3‐month‐old AT‐1 sTg mice are shown for comparison.
Representative blots are shown in (e) while quantitation of results is shown in (f) (n = 6 for all groups). (g) Structure illumination microscopy
(SIM) of ER in isolated hepatocytes from compound 9‐treated AT‐1 sTg mice. Dox‐treated and 3‐month‐old AT‐1 sTg mice are shown for
comparison. (h) High‐magnification images with Imaris‐mediated reconstruction. Bars represent mean ± SD. *p < 0.05, **p < 0.005,
#p < 0.0005. N: nucleus
12 of 17 | PENG ET AL.
architecture of the nuclear envelope or in the DNA repairing
machinery; associated animal models reproduce the nuclear and
genomic instability and mimic the progeroid phenotype (reviewed in
(Kubben & Misteli, 2017)). Exceptions to the above are the p53/p44
and the AT‐1 sTg systems. In the case of p53/p44, the primary
defect is in the N‐terminal regulatory functions of the p53 protein,
which leads to reduced stemness potential of stem cells as well as
hyperactivation of IGF‐1R signaling (Campisi, 2004; Lessel et al.,
2017; Maier et al., 2004; Pehar, Ko, Li, Scrable, & Puglielli, 2014;
Tyner et al., 2002). AT‐1 sTg mice display many features that are in
line with classical segmental progerias, such as reduced growth,
alopecia, skin lesions, rectal prolapse, osteoporosis, cardiomegaly,
muscle atrophy, reduced fertility, and systemic inflammation. Unlike
classical progerias, they do not display nuclear/genomic instability,
reduced stemness potential of stem cells, or hyperactivation of IGF‐
1R signaling. Also in contrast with classical progerias, AT‐1 sTg mice
display metabolic‐linked features that are not typically observed in
patients with progeria. We contend that the AT‐1 sTg mouse repre-
sents the first model of progeria‐like phenotype where the primary
defect is in the regulation of intracellular acetyl‐CoA flux, reticu-
lophagy, and proteostatic functions of the ER. In light of the known
association between dysfunctional autophagy and age‐associated dis-
eases (Kroemer, 2015; Madeo, Tavernarakis, & Kroemer, 2010;
Madeo, Zimmermann, Maiuri, & Kroemer, 2015), we can speculate
that AT‐1 sTg mice will offer new mechanistic and therapeutic ave-
nues for several age‐associated diseases.
3.2 | The progeria‐like phenotype of AT‐1 sTg mice
is caused by a block in reticulophagy
Our data suggest that defects in reticulophagy, perhaps accompanied
by opposite changes in efficiency of the secretory pathway (Hullinger
et al., 2016; Peng & Puglielli, 2016), may causally contribute to the
progeria‐like phenotype of the AT‐1 sTg mice. In AT‐1 sTg mice, retic-
ulophagy is linked to the acetylation status of Atg9a indicating that
acetyl‐coA flux is a key input for maintenance of ER homeostatic
mechanisms (see Supporting Information Figure S8). We have previ-
ously shown that Atg9a acts as a sensor of the ER acetylation
machinery; indeed, downregulation or expression of hypomorphic AT‐
1 lowers levels of acetylation of Atg9a and induces autophagy, while
overexpression of AT‐1 leads to increased acetylation of Atg9a and a
block in autophagy induction (Pehar et al., 2012; Peng & Puglielli,
2016; Peng et al., 2014). Importantly, gain‐of‐acetylation and loss‐of‐
acetylation mutants of Atg9a can recapitulate the events reported
above, thus providing mechanistic support (Pehar et al., 2012).
New results reported in this study indicate that functional Atg9a‐
Fam134b and Atg9a‐Sec62 association is an initial and essential step
for reticulophagy and that these interactions can occur only when
Atg9a is not acetylated, highlighting the importance of acetylation
on multiple levels in proteostatic control (see Supporting Information
Figure S8). Fam134b is an integral ER membrane protein that acts as
a “receptor” for reticulophagy (Khaminets et al., 2015; Mochida
et al., 2015; Rubinsztein, 2015). It was recently identified in both
yeast and mammalian cells (Khaminets et al., 2015; Mochida et al.,
2015; Rubinsztein, 2015). Interestingly, Fam134b seems to preferen-
tially localize on ER sheet‐like (rough ER) structures, where the bulk
of protein biosynthesis normally occurs, and might act as part of
quality control to couple protein biosynthesis to disposal of
unfolded/misfolded polypeptides (Nakatogawa & Mochida, 2015).
Sec62, an integral member of the ER translocon machinery, also
seems to act as an ER‐resident autophagy “receptor” (Fumagalli
et al., 2016). Sec62 is also thought to be involved in coupling the
insertion of newly synthesized proteins into the ER with the regula-
tory mechanisms that detect and dispose of unfolded/misfolded
polypeptides (Schuck, 2016). Both Fam134b and Sec62 require phys-
ical interaction with LC3β to exert their functions (Fumagalli et al.,
2016; Khaminets et al., 2015; Mochida et al., 2015; Rubinsztein,
2015; Schuck, 2016). The fact that Atg9a acetylation status directs
the formation of Sec62 and Fam134b complexes, sequestering them
from the essential binding partner LC3β, suggests coordination of
events to influence reticulophagy (see Supporting Information Fig-
ure S8). The specific contribution of enhanced efficiency of the
secretory pathway to the progeria phenotype of AT‐1 sTg mice
remains to be determined.
3.3 | Biochemical inhibition of the ATases
downstream of AT‐1 restores reticulophagy and
rescues the progeria‐like phenotype
The impact of pharmacological inhibition of the acetyltransferases,
ATase1 and ATase2, is an exciting development and one that may
have clinical application. ATase1 and ATase2 act downstream of AT‐
1 to acetylate ER cargo proteins (Ko & Puglielli, 2009), regulate the
acetylation status of Atg9a, and are essential for the proteostatic
functions of the ER acetylation machinery (Ding et al., 2014; Peng
et al., 2016). Our study showed that inhibition of the ATases was
able to restore the Atg9a‐Fam134b‐LC3β and Atg9a‐Sec62‐LC3β
interaction at the ER membrane and rescue the progeria‐like pheno-
type of AT‐1 sTg mice. Overexpression of AT‐1 in the mouse seems
to recapitulate the outcomes of children with duplications of the
3q25.31 locus (containing AT‐1/SLC33A1). In this study, treatment
with compound 9 was initiated at weaning when the disease mani-
festations were already developing. This suggests that strategies
based on similar targeting might be effective in treating the human
disease, where early diagnosis and early treatment could mitigate or
even prevent disease manifestations.
While recognizing the intrinsic limitations of a single gene‐directed
progeria model, several aspects of the phenotype developed by AT‐1
sTg mice mimic accelerated forms of pathogenic aging. Therefore, the
model may provide insights into a range of age‐related diseases and
conditions, and studies on ATase1/ATase2 inhibitors might be rele-
vant for chronic diseases linked to proteostatic dysfunction. For
example, the entire ER acetylation machinery, AT‐1 (Gomez Ravetti,
Rosso, Berretta, & Moscato, 2010; Jonas et al., 2010) and the ATases
(Ding et al., 2012), is upregulated in patients with late‐onset Alzhei-
mer's disease, the most common form of age‐associated dementia.
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Importantly, both haploinsufficiency of AT‐1 and biochemical inhibi-
tion of the ATases using compound 9 were able to rescue the Alzhei-
mer's disease‐like phenotype in the mouse (Duran‐Aniotz, Cornejo, &
Hetz, 2016; Peng et al., 2016). We are eager to further explore these
models and strategies that we believe will have utility in a broader
context of aging and age‐related disease.
4 | CONCLUSION
In conclusion, our study shows that systemic overexpression of AT‐1
in the mouse causes a progeria‐like phenotype with metabolic alter-
ations. Mechanistically, the phenotype is caused by a block in Atg9a‐
Fam134b‐LC3β and Atg9a‐Sec62‐LC3β interaction, which prevents
the induction of reticulophagy. Our study also shows that restoring
the proteostatic functions of the ER, by targeting the ATases down-
stream of AT‐1, can rescue the mouse phenotype, thus suggesting
that ATase1/ATase2 inhibitors might offer translational opportunities
for patients with AT‐1/SLC33A1 duplications and for the mitigation
of different age‐associated diseases. Finally, this study sets the foun-
dation for new inquiries into the mechanisms that regulate intracellu-
lar acetyl‐CoA flux and availability, and how they can influence
disease phenotypes that have not been traditionally viewed as pri-
marily driven by metabolic changes.
5 | EXPERIMENTAL PROCEDURES
5.1 | Transgenic animals
pTRE‐AT‐1 Tg mice were described previously (Hullinger et al.,
2016). ROSA:LNL:tTA (Gt(ROSA)26Sortm1(tTA)Roos/J; JAX Stock No:
011008) were bred to EIIa‐Cre (B6.FVB‐Tg(EIIa‐cre)C5379Lmgd/J;
JAX Stock No: 003724), generating Rosa26:tTA mice which univer-
sally express tTA. Rosa26:tTA mice were then crossed with pTRE‐
AT‐1 mice to generate ROSA26:tTA;pTRE‐AT‐1 (referred to as AT‐1
sTg) mice. Genotyping from tail DNA was performed using the fol-
lowing primers: AT‐1 forward (5′‐AAT CTG GGA AAC TGG CCT
TCT‐3′), AT‐1 reverse (5′‐TAT TAC CGC CTT TGA GTG AGC TGA‐
3′), Rosa forward (5′‐AAA GTC GCT CTG AGT TGT TAT‐3′), and
Rosa reverse (5′‐GCG AAG AGT TTG TCC TCA ACC‐3′). Both males
and females were studied. Wild‐type (WT) littermates were used as
controls throughout our study. Unless specified, living AT‐1 sTg mice
were studied at the age of approx. 3 months.
The rodent diet with Compound 9 was manufactured by Bio‐
Serv. The food with doxycycline (200 mg/kg) was purchased from
Bio‐Serv. The same diet without Compound 9 or doxycycline served
as the control diet.
All animal experiments were carried out in accordance with the
NIH Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care and Use Committee of
the University of Wisconsin‐Madison and the Madison Veterans
Administration Hospital.
5.2 | Cell cultures
Mouse embryonic fibroblasts (MEFs) from wild‐type and AT‐1 sTg
mice were prepared as described previously (Peng et al., 2014). Fur-
ther details are in Supporting Information.
5.3 | Hepatocyte isolation
Hepatocytes were isolated and analyzed as described in Supporting
Information.
5.4 | Protein extraction, western blotting, and
immunoprecipitation
Protein extraction, western blotting, and immunoprecipitation tech-
niques are described in Supporting Information.
5.5 | Dot blots
Dot blot analysis was performed as described in Supporting Informa-
tion.
5.6 | Real‐time PCR
Real‐time PCR was performed as described before (Jonas et al.,
2010). Further details are in Supporting Information.
5.7 | Histology and bone histomorphometry
Histology and bone histomorphometry were performed as described
in Supporting Information.
5.8 | Faxitron radiography and dual‐energy X‐ray
absorptiometry
Dual‐energy X‐ray absorptiometry analysis was conducted as
described in Supporting Information.
5.9 | Whole blood, serum, and plasma analytes
Blood, serum, and plasma analytes were determined as in Supporting
Information.
5.10 | Blood and bone marrow smear examination
Fresh whole blood or bone marrow samples were smeared as in
Supporting Information.
5.11 | Flow cytometry
Flow cytometry was performed as in Supporting Information.
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5.12 | Erythroid progenitor assays
Erythroid progenitor assays were performed as in Supporting Infor-
mation.
5.13 | Bone marrow transplantation
Bone marrow transplantation experiments were performed as
described previously (Wang et al., 2011). Further details are in Sup-
porting Information.
5.14 | Senescence‐associated β‐galactosidase
staining
Senescence β‐galactosidase staining was performed as in Supporting
Information.
5.15 | OGTT, glucose, insulin, and glucagon assays
OGTT, glucose, insulin, and glucagon assays were performed as in
Supporting Information.
5.16 | Echocardiography
Transthoracic echocardiography was performed as described previ-
ously (Harris et al., 2002). Further details are in Supporting Informa-
tion.
5.17 | Trafficking of newly synthetized
glycoproteins
Quantification of trafficking glycoproteins along the secretory path-
way was performed as previously described (Hullinger et al., 2016).
Further details are in Supporting Information.
5.18 | Statistics
Data analysis was performed using GRAPHPAD INSTAT 3.06 statistical
software (GraphPad Software Inc.). Data are expressed as mean ± s-
tandard deviation (SD). Comparison of the means was performed
using Student's t‐test or one‐way ANOVA followed by Tukey–Kra-
mer multiple comparisons test. For lifespan assessment, data were
analyzed with the Kaplan–Meier lifespan test and log‐rank test using
GRAPHPAD PRISM version 7.03 (GraphPad Software). Differences were
declared statistically significant if p < 0.05.
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